Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $14,250.00 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $4.75, for a total transaction of $14,250.00. Following the completion of the transaction, the director now directly owns 141,950 shares in the company, valued at $674,262.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

John Joseph Johnston also recently made the following trade(s):

• On Thursday, June 27th, John Joseph Johnston sold 10,000 shares of MaxCyte stock. The shares were sold at an average price of $3.99, for a total transaction of $39,900.00.

MaxCyte Stock Performance

MXCT opened at $4.57 on Friday. The company’s 50 day moving average is $4.46 and its 200-day moving average is $4.46. MaxCyte, Inc. has a 1-year low of $2.45 and a 1-year high of $5.55.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. The business had revenue of $11.34 million during the quarter, compared to analyst estimates of $7.75 million. MaxCyte had a negative net margin of 83.00% and a negative return on equity of 15.68%. On average, equities analysts expect that MaxCyte, Inc. will post -0.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in MaxCyte by 15.3% in the 2nd quarter. Rhumbline Advisers now owns 157,616 shares of the company’s stock valued at $618,000 after buying an additional 20,864 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in MaxCyte by 22.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock worth $128,000 after purchasing an additional 5,927 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in MaxCyte by 24.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 423,209 shares of the company’s stock worth $1,659,000 after purchasing an additional 83,025 shares during the last quarter. Chevy Chase Trust Holdings LLC raised its holdings in MaxCyte by 2.0% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 1,322,560 shares of the company’s stock worth $5,184,000 after purchasing an additional 26,163 shares during the last quarter. Finally, Swedbank AB bought a new position in MaxCyte during the 1st quarter worth approximately $6,704,000. Institutional investors own 68.81% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an “overweight” rating and set a $11.00 price objective on shares of MaxCyte in a research note on Tuesday, April 23rd.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.